Clinical trials
Kaposi Sarcoma clinical trials
Below are recruiting kaposi sarcoma clinical trials, each written for real people, not researchers. We’re tracking 19 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04305691RecruitingPhase 2
Ixazomib for skin Kaposi sarcoma in people with HIV
This trial studies ixazomib (a targeted anti-cancer medicine) to treat cutaneous (skin) Kaposi sarcoma. It aims to shrink measurable skin lesions and improve symptoms, especially in people living with HIV.
San Diego, CaliforniaAges 18 years+ - NCT04303117RecruitingPhase 1/Phase 2
Test drug PDS01ADC alone and with immunotherapy for Kaposi sarcoma
This Phase 1/2 study tests PDS01ADC, a targeted cancer drug, for advanced Kaposi sarcoma (KS). It also studies how well the drug works when added to the immunotherapy M7824, especially if KS has not responded to prior treatments.
Bethesda, MarylandAges 18–99 - NCT04941274RecruitingPhase 1/Phase 2
Abemaciclib for Kaposi sarcoma in people with or without HIV
This Phase 1/2 study tests the medicine abemaciclib to shrink Kaposi sarcoma (KS) lesions and control the disease. It includes both people with HIV and people without HIV, and may help when KS has not responded well to prior treatment or when certain KS stages are present.
Bethesda, MarylandAges 18–99 - NCT06375122Recruiting
A study of Kaposi sarcoma over time
This study follows people with Kaposi sarcoma to learn more about the disease and how it changes over time. It may help doctors better understand and treat KS in the future.
Bethesda, MarylandAges 18–120 - NCT07066982RecruitingPhase 1/Phase 2
CAR T cells targeting CD146 and HER2 for advanced sarcomas
This trial tests a new type of immunotherapy where your own immune cells are modified to find and attack sarcoma cells that carry markers called CD146 or HER2. It is for people with advanced sarcoma who have already tried standard treatments.
Beijing, Beijing MunicipalityAges 21–90 - NCT06898203Recruiting
Precision imaging for Kaposi sarcoma
This trial uses advanced imaging to better understand Kaposi sarcoma. If you are starting or already receiving treatment, researchers want to see how imaging can help track your cancer.
KisumuAges 18 years+ - NCT05663502Recruiting
Donate blood and tissue samples for HIV-related cancer research
This study collects blood and tissue samples to help researchers learn more about cancers related to HIV/AIDS. You may be able to join if you’re 18+ and have HIV and a cancer diagnosis, or (if HIV-negative) a certain cancer that is closely linked to AIDS-related cancers.
La Jolla, CaliforniaAges 18 years+ - NCT06445166RecruitingPhase 2
Propranolol for Kaposi Sarcoma in adults
This trial tests if the blood pressure medication propranolol can treat Kaposi Sarcoma (a type of skin cancer) in adults. You may be able to join if you have at least 7 measurable skin lesions and are otherwise healthy enough to take an oral pill.
St Louis, MissouriAges 18 years+ - NCT06751355Recruiting
Precision imaging for Kaposi sarcoma
This trial tests a special imaging device to see if it can better evaluate Kaposi sarcoma skin lesions. It may help doctors understand the extent of the disease without relying only on physical exams.
St Louis, MissouriAges 18 years+ - NCT06236022RecruitingPhase 4
Sirolimus for dilated cardiomyopathy with KSHV infection
This trial tests whether the drug sirolimus (rapamycin) can help people with dilated cardiomyopathy who also have a specific virus (KSHV) in their blood. It aims to see if sirolimus can improve heart function.
Wuhan, HubeiAges 18–70 - NCT07308886RecruitingPhase 2
CYT107 for Kaposi sarcoma in HIV patients with low CD4
This trial tests an experimental drug (CYT107) that boosts the immune system to help fight Kaposi sarcoma in people with HIV who have a low CD4 count despite good HIV treatment. It aims to see if the drug can improve KS tumors and quality of life.
Bethesda, MarylandAges 18–120 - NCT06052618RecruitingPhase 2
Pacritinib for KSHV-associated Castleman disease and KICS
This study tests a drug called pacritinib for people with KSHV-associated multicentric Castleman disease (MCD) or KSHV-associated inflammatory cytokine syndrome (KICS). It aims to see if the drug can help control symptoms and inflammation caused by these conditions.
Bethesda, MarylandAges 18–120 - NCT06638931RecruitingPhase 2
Nivolumab for rare solid tumors with high PD-L1
This trial is testing a drug called Nivolumab (an immunotherapy) for people with rare solid tumors that have high levels of PD-L1. It might be an option if you have tried other treatments and they stopped working or caused too many side effects.
Fortaleza, CearáAges 18 years+ - NCT07793006Recruiting
New ways to diagnose lymphoma and castleman disease
This study tests new methods to diagnose lymphoma and multicentric castleman disease, which are conditions that can affect people with HIV. It may help find these diseases earlier and more accurately.
LilongweAges 1 year+ - NCT04902443RecruitingPhase 1
Pomalidomide plus nivolumab for virus-related cancers
This trial studies pomalidomide plus nivolumab in people with cancers linked to certain viruses (or hepatitis B/C). It may help the immune system fight the cancer when the disease has returned, progressed, or can’t be fully treated with standard options.
Bethesda, MarylandAges 18–99 - NCT05859074RecruitingPhase 1
Testing MQ710 injections alone or with pembrolizumab for advanced cancers
This early-phase study tests MQ710, a medicine given by injection into a reachable tumor, to see how well it can control advanced cancers. Some participants also receive pembrolizumab, an immunotherapy, to help the immune system fight the cancer.
Basking Ridge, New JerseyAges 18 years+ - NCT06004011Recruiting
Cancer workforce roles for people living with HIV
This study looks at a program to help people living with HIV take on cancer-fighting roles (like caregiving or support workers). It follows volunteers for 3 years and checks how well the program works for them and their community.
LusakaAges 15–39 - NCT00006518Recruiting
Tissue samples from people with viral infections or cancer
This study collects tissue and blood samples from people who have or have been exposed to certain viruses (HIV, KSHV, HPV, EBV, or HTLV-1) or who have developed cancer or precancerous skin lesions. The samples help researchers understand how these viruses may lead to cancer.
Bethesda, MarylandAges 18–120 - NCT03300830Recruiting
Testing tumors linked to viruses, HIV, and immune disorders
This study collects and analyzes tumor tissue to learn what drives certain cancers and growths linked to viruses, HIV, and immune system problems. Results may help researchers understand disease causes and point to better future treatments.
Bethesda, MarylandAges 18 years+
Hear when a new Kaposi Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Kaposi Sarcoma trials by city
Studies with a site in or near these metro areas.
Kaposi Sarcoma trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for kaposi sarcoma?
- Yes. Clin2 currently lists 19 recruiting kaposi sarcoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a kaposi sarcoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a kaposi sarcoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.